Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH) shares fell 0.88%, or $0.03 per share, to close Monday at $3.39. After opening the day at $3.39, shares of Reviva fluctuated between $3.44 and $3.38. 23,153 shares traded hands a decrease from their 30 day average of 90,837. Monday's activity brought Reviva’s market cap to $31,295,588.

About Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals, Inc. is a clinical stage pharmaceutical company developing therapies that address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases. Reviva's primary focus is developing its lead product candidate, RP5063 (brilaroxazine), for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. Reviva also intends to develop RP5063 for treating PAH and IPF. RP5063 is a serotonin, dopamine, and nicotinic receptor active compound, which has successfully completed a global Phase 2 clinical trial and has shown clinical efficacy and safety for schizophrenia and schizoaffective disorder.

Visit Reviva Pharmaceuticals Holdings Inc.’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Reviva Pharmaceuticals Holdings Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: Reviva Pharmaceuticals Holdings Inc.’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

FAA Urges Airlines To Take Stronger Action With Unruly, Disruptive Passengers

Freshworks Leaps 32% on First Day of Trading After Pricing Above Filing Range

Twitter Settles Class Action for $809.5 Million Over Providing Misleading Information to Investors

DoorDash Adds Alcohol Delivery in 20 US States, DC, Canada, Australia

Bill Gates Raises More Than $1 Billion for Clean Energy Technology

CVS Health To Hire 25,000 in Virtual Career Event Friday September 24

President Biden's New Alliance With Australia and Britain Angers France and European Union

California Governor Newsom Signs Affordable Housing Law